| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10919111 | Radiotherapy and Oncology | 2013 | 5 Pages |
Abstract
PSA relapse-free survival rates after SBRT compare favorably with other definitive treatments for low and intermediate risk patients. The current evidence supports consideration of SBRT among the therapeutic options for these patients.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Christopher R. King, Debra Freeman, Irving Kaplan, Donald Fuller, Giampaolo Bolzicco, Sean Collins, Robert Meier, Jason Wang, Patrick Kupelian, Michael Steinberg, Alan Katz,